This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
BMYPositive Net Change NBIXNegative Net Change ABBVNegative Net Change FULCNegative Net Change
medical pharmaceuticals
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
by Zacks Equity Research
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
ALNYNegative Net Change NVSPositive Net Change LLYNegative Net Change EXELNegative Net Change
biotechnology medical pharmaceuticals
Bayer, NextRNA to Develop Therapeutics Targeting Oncology
by Zacks Equity Research
BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.
LLYNegative Net Change BAYRYPositive Net Change EXELNegative Net Change
medical pharmaceuticals
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
by Kinjel Shah
GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
GSKNegative Net Change NVOPositive Net Change LLYNegative Net Change HLNNegative Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
by Zacks Equity Research
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
JNJNegative Net Change LLYNegative Net Change KVUENegative Net Change
pharmaceuticals
Top Analyst Reports for Linde, AstraZeneca & Walt Disney
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and The Walt Disney Company (DIS), as well as two micro-cap stocks FitLife Brands, Inc. (FTLF) and Utah Medical Products, Inc. (UTMD).
AZNPositive Net Change BPNegative Net Change VNegative Net Change CNINegative Net Change DISPositive Net Change UTMDPositive Net Change FTLFNegative Net Change SONYNegative Net Change
business-services consumer-discretionary medical pharmaceuticals
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
by Zacks Equity Research
LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
pharmaceuticals
J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.
JNJNegative Net Change LLYNegative Net Change KVUENegative Net Change
pharmaceuticals
J&J's Rybrevant Receives EU Approval for Expanded Use in NSCLC
by Zacks Equity Research
The European Commission approves JNJ's Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
AZNPositive Net Change JNJNegative Net Change ILMNPositive Net Change FULCNegative Net Change
pharmaceuticals
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
by Zacks Equity Research
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
MRKPositive Net Change ILMNPositive Net Change KRYSNegative Net Change FULCNegative Net Change
pharmaceuticals
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
by Zacks Equity Research
PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.
PFENegative Net Change LLYNegative Net Change FULCNegative Net Change BVSPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
by Zacks Equity Research
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
JNJNegative Net Change FULCNegative Net Change ADXNNegative Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
ACADPositive Net Change SLNOPositive Net Change FULCNegative Net Change BVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
by Ekta Bagri
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGNNegative Net Change LXRXPositive Net Change GLPGNegative Net Change RYTMPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
AZNPositive Net Change RHHBYPositive Net Change LLYNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
by Zacks Equity Research
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Insmed Stock Surges 168% in the Past Six Months: Here's Why
by Zacks Equity Research
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
AZNPositive Net Change INSMNegative Net Change FULCNegative Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
by Zacks Equity Research
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
ARCTNegative Net Change RYTMPositive Net Change FULCNegative Net Change BVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
by Zacks Equity Research
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
JNJNegative Net Change MRKPositive Net Change LLYNegative Net Change UTHRNegative Net Change
pharmaceuticals
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
GSKNegative Net Change GILDPositive Net Change MRUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Eli Lilly, Chevron & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Chevron Corporation (CVX) and Abbott Laboratories (ABT), as well as a micro-cap stocks Bridger Aerospace Group Holdings, Inc. (BAER).
ABTNegative Net Change CVXPositive Net Change LLYNegative Net Change OXYNegative Net Change BCEPositive Net Change PSXPositive Net Change BAERNegative Net Change
aerospace medical oil-energy pharmaceuticals
AstraZeneca (AZN) Denies Rumors About UK Facility Relocation
by Zacks Equity Research
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
AZNPositive Net Change ARCTNegative Net Change FULCNegative Net Change BVSPositive Net Change
biotechs medical pharmaceuticals vaccines
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
by Zacks Equity Research
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
ARCTNegative Net Change STRONegative Net Change FULCNegative Net Change BVSPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's Why You Should Consider Buying Akebia (AKBA) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
RHHBYPositive Net Change LLYNegative Net Change ARCTNegative Net Change AKBANegative Net Change
pharmaceuticals